Ipsen gains access to ADC from Shanghai biotech Simcere Zaimingnews2025-12-22T14:12:36+00:00December 22nd, 2025|Endpoints News|
Boehringer taps Rectify to create pills for chronic kidney diseasenews2025-12-22T13:00:04+00:00December 22nd, 2025|Endpoints News|
AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancernews2025-12-22T12:09:55+00:00December 22nd, 2025|Endpoints News|
BioMarin to pay $4.8B for Amicus and its rare disease drugsnews2025-12-19T16:10:45+00:00December 19th, 2025|Endpoints News|
Joe Jimenez’s Aditum goes to Fosun for major biobuck-loaded collaborationnews2025-12-19T13:15:31+00:00December 19th, 2025|Endpoints News|
GSK turns to Camp4 for neuro and kidney medicinesnews2025-12-18T12:00:26+00:00December 18th, 2025|Endpoints News|
RTW’s Yarrow to go public in reverse merger with Vyne Therapeuticsnews2025-12-17T15:47:20+00:00December 17th, 2025|Endpoints News|
Harbour makes $90M upfront deal with Bristol Myers for new antibodiesnews2025-12-17T00:03:06+00:00December 17th, 2025|Endpoints News|
RTW startup signs autoimmune antibody pact with China’s GenScinews2025-12-16T12:28:24+00:00December 16th, 2025|Endpoints News|
Sanofi licenses ADEL’s tau-targeting Alzheimer’s drug for $80M upfrontnews2025-12-16T12:06:35+00:00December 16th, 2025|Endpoints News|
